US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

266.44

+0.65000.24%

Post-market: 266.440.00000.00%19:30 EDT

Volume:51.13K

Turnover:13.62M

Market Cap:2.92B

PE:31.18

High:267.47

Open:267.37

Low:265.26

Close:265.79

52wk High:275.23

52wk Low:182.08

Shares:10.95M

Float Shares:10.95M

Volume Ratio:0.23

T/O Rate:0.47%

Dividend:- -

Dividend Rate:- -

EPS(TTM):8.55

EPS(LYR):37.75

ROE:19.96%

ROA:-0.16%

PB:1.05

PE(LYR):7.06

Loading ...

Overview Company News Filings

uniQure seeks accelerated approval for Huntington’s gene therapy

Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson Disposes of 9,000 Shares for $422,874

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

Novartis halts autoimmune CAR-T trials following three deaths, Reuters says

Circio boosts circVec gene therapy data and secures funding runway to 2030

Corcept Therapeutics Insider Makes Major Multimillion-Dollar Stock Move

Labcorp to Present at Morgan Stanley Healthcare Conference

Corcept Endocrinology President Sean Maduck Disposes of 30,955 Corcept Shares Worth $3.88 Million

Analysts Have Conflicting Sentiments on These Healthcare Companies: NeoGenomics (NEO) and Medtronic (MDT)

NeoGenomics RaDaR ST Gains Expanded Medicare Coverage for Immunotherapy Response Monitoring

Neogenomics Receives Medicare Coverage for Radar St for Immunotherapy Treatment Response Monitoring

THOMSON REUTERS

Circio and Full Circles join forces on non-viral in vivo cell therapy platform

Court Win Over Natera Patents Could Be A Game Changer For NeoGenomics’ (NEO) RaDaR ST

Simply Wall St.

Circio bolsters board as it advances circular RNA gene therapy platform

Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study

The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1

THOMSON REUTERS

Veracyte (VCYT) Receives a Buy from Piper Sandler

Is Bruker’s (BRKR) AI Bet With Atinary Quietly Redefining Its Long-Term R&D Strategy?

Simply Wall St.

Regenxbio reports FDA placed clinical hold on RGX-121

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/FBT/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"FBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","market":"US","secType":"STK","nameCN":"First Trust NYSE Arca Biotechnology Index Fund","latestPrice":266.44,"timestamp":1790971200000,"preClose":265.79,"halted":0,"volume":51129,"hourTrading":{"tag":"盘后","latestPrice":266.44,"preClose":266.44,"latestTime":"19:30 EDT","volume":18,"amount":4793.6848,"timestamp":1790983804969,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.002445539711802465,"floatShares":10950002,"shares":10950002,"eps":8.545272,"marketStatus":"Market Closed","change":0.65,"latestTime":"10-02 16:00:00 EDT","open":267.37,"high":267.465,"low":265.2589,"amount":13615858.23858,"amplitude":0.0083,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":8.545272,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":265.79,"sharesOutstanding":11450002,"nav":265.84,"aum":2897656531.68,"bidAskSpread":0.000914,"preHourTrading":{"tag":"盘前","latestPrice":265.84,"preClose":265.79,"latestTime":"07:07 EDT","volume":21,"amount":5569.2,"timestamp":1790939266223,"change":0.05,"changeRate":0.000188,"amplitude":0.008428},"postHourTrading":{"tag":"盘后","latestPrice":266.44,"preClose":266.44,"latestTime":"19:30 EDT","volume":18,"amount":4793.6848,"timestamp":1790983804969,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.23051848500740743,"impliedVol":0.2223,"impliedVolPercentile":0.6972},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","floatShares":10950002,"roa":"-0.16%","roe":"19.96%","lyrEps":37.754725,"volumeRatio":0.23051848500740743,"shares":10950002,"dividePrice":0,"high":267.465,"amplitude":0.0083,"preClose":265.79,"low":265.2589,"week52Low":182.08,"pbRate":"1.05","psRate":"703.82","week52High":275.23,"institutionHeld":0,"latestPrice":266.44,"eps":8.545272,"divideRate":0,"volume":51129,"delay":0,"ttmEps":8.545272,"open":267.37,"prevYearClose":206.52,"prevWeekClose":272.86,"prevMonthClose":272.26,"prevQuarterClose":272.26,"fiveDayClose":272.86,"twentyDayClose":273.79,"sixtyDayClose":256.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBT\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FBT","amount":1.1726,"announcedDate":"2024-12-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust NYSE Arca Biotechnology Index Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"},{"market":"US","date":"2022-01-10","symbol":"FBT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1641790800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2021-12-30","symbol":"FBT","amount":2.2136,"defaultRemindTime":1640874600000,"name":"First Trust NYSE Arca Biotechnology Index Fund","recordDate":"2022-01-10","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-10","value":2.2136,"currency":"USD"},{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":1.1726,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBT\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664819175","title":"uniQure seeks accelerated approval for Huntington’s gene therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819175","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664819175?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:59","pubTimestamp":1788350375,"startTime":"0","endTime":"0","summary":"The latest update is out from uniQure ( ($QURE) ). On September 2, 2026, uniQure submitted a Biologics License Application to the U.S. Food and Dru...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/uniqure-seeks-accelerated-approval-for-huntingtons-gene-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/uniqure-seeks-accelerated-approval-for-huntingtons-gene-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNCR","IBBQ","BK4585","TBXU","LFSC","BK4588","SYNB","IBB","FBT","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664864142","title":"Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson Disposes of 9,000 Shares for $422,874","url":"https://stock-news.laohu8.com/highlight/detail?id=2664864142","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664864142?lang=en_us&edition=fundamental","pubTime":"2026-09-02 07:09","pubTimestamp":1788304180,"startTime":"0","endTime":"0","summary":"Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson disposes of 9,000 shares for $422,874Craig C. Hopkinson, EVP R&D, Chief Medical Officer, sold 9,000 ordinary shares on Sep. 1 at USD 46.99.He","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDLgbNz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson Disposes of 9,000 Shares for $422,874","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","PSCH","MEDX","BK4139","IBRN","FBT","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664869470","title":"Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664869470","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664869470?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:05","pubTimestamp":1788293100,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chatat the Morga","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354590/0/en/veracyte-to-participate-in-the-morgan-stanley-24th-annual-global-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","FBT","BK4588","BK4137","BK4585","LABU","LU0128526141.USD","LU0029874061.USD","BK4581","XBI","MS","BK4139","XLV","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664856297","title":"Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664856297","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664856297?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:00","pubTimestamp":1788264000,"startTime":"0","endTime":"0","summary":"BRIDGEWATER N.J., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354079/0/en/legend-biotech-to-participate-in-the-morgan-stanley-global-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4505","XBI","FBT","XLV","TBXU","GNOM","BK4588","BK4137","MEMS","IBB","SYNB","HCSG","CNCR","LU0029874061.USD","LFSC","LU0128526141.USD","LABU","BK4581","LEGN","MEDI","CANC","BK4139","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664985383","title":"Novartis halts autoimmune CAR-T trials following three deaths, Reuters says","url":"https://stock-news.laohu8.com/highlight/detail?id=2664985383","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664985383?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:30","pubTimestamp":1788258648,"startTime":"0","endTime":"0","summary":"Novartis (NVS) has paused eight clinical trials of rap-cel, an experimental cell therapy targeting autoimmune and neurological disorders, after thr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-halts-autoimmune-car-t-trials-following-three-deaths-reuters-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-halts-autoimmune-car-t-trials-following-three-deaths-reuters-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPH","TBXU","IE00BJT1NW94.SGD","NVIB","HYLG","LU0320765489.SGD","LU0208291251.USD","GDOC","IE0009355771.USD","BMED","LU0211331839.USD","BK4007","BK4585","LFSC","SYNB","IE00BFTCPJ56.SGD","IBBQ","BK4532","BK4578","MEDX","IDNA","IE00BJJMRZ35.SGD","IBB","FBT","LU0070302665.USD","BK4588","NVS","CNCR","IE0002141913.USD","GNOM","IE00B2B36J28.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664000711","title":"Circio boosts circVec gene therapy data and secures funding runway to 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2664000711","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664000711?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:03","pubTimestamp":1788203022,"startTime":"0","endTime":"0","summary":"The latest update is out from Targovax ASA ( ($GB:0RIS) ). Circio Holding ASA reported that new preclinical data show its circVec circular RNA tech...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/circio-boosts-circvec-gene-therapy-data-and-secures-funding-runway-to-2030?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/circio-boosts-circvec-gene-therapy-data-and-secures-funding-runway-to-2030?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYNB","GNOM","TBXU","BK4588","BK4585","BK4505","IBB","BK4139","CNCR","IE0009354923.USD","IBBQ","FBT","LFSC","RNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663011648","title":"Corcept Therapeutics Insider Makes Major Multimillion-Dollar Stock Move","url":"https://stock-news.laohu8.com/highlight/detail?id=2663011648","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663011648?lang=en_us&edition=fundamental","pubTime":"2026-08-29 10:06","pubTimestamp":1787969183,"startTime":"0","endTime":"0","summary":"New insider activity at Corcept Therapeutics ( ($CORT) ) has taken place on August 28, 2026. Director Park Kimberly has recently cashed out a signi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/corcept-therapeutics-insider-makes-major-multimillion-dollar-stock-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/corcept-therapeutics-insider-makes-major-multimillion-dollar-stock-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","LU0566484027.USD","FBT","CORT","LU1559883803.SGD","BK4007","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662009682","title":"Labcorp to Present at Morgan Stanley Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2662009682","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662009682?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:36","pubTimestamp":1787924191,"startTime":"0","endTime":"0","summary":"Labcorp Holdings ( ($LH) ) has issued an announcement. Labcorp Holdings Inc., a global leader in diagnostics and drug development laboratory servic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/labcorp-to-present-at-morgan-stanley-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/labcorp-to-present-at-morgan-stanley-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0029874061.USD","XBI","BK4588","FBT","XLV","BK4137","HCSG","LFSC","LU0128526141.USD","LABU","BMED","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662033320","title":"Corcept Endocrinology President Sean Maduck Disposes of 30,955 Corcept Shares Worth $3.88 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662033320","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662033320?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:31","pubTimestamp":1787862696,"startTime":"0","endTime":"0","summary":"Corcept Endocrinology President Sean Maduck disposes of 30,955 Corcept shares worth $3.88 millionCorcept Therapeutics President, Corcept Endocrinology Sean Maduck exercised stock options for 30,955 co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDLbYdy60:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Endocrinology President Sean Maduck Disposes of 30,955 Corcept Shares Worth $3.88 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","CORT","PSCH","LU0566484027.USD","LU1559883803.SGD","FBT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703720","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: NeoGenomics (NEO) and Medtronic (MDT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662703720?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:10","pubTimestamp":1787825408,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on NeoGenomics (NEO) and Medtronic (MDT). NeoGenomics...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-neogenomics-neo-and-medtronic-mdt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-neogenomics-neo-and-medtronic-mdt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","LU0158827781.USD","FBT","IE00BFXG1179.USD","HCSG","LU1571399168.USD","IE000M9KFDE8.USD","LU2089984988.USD","BK4137","LU0208291251.USD","LU1116320737.USD","IE00BVYPNW00.USD","LU1983299246.USD","IE00BGHQF631.EUR","MDT","LU0072461881.USD","LU1244550494.USD","BK4588","IE00B3PB1722.GBP","LU0211326839.USD","LU1116320901.HKD","LU2023251221.USD","LU0211331839.USD","BK4196","BK4581","LU0162691827.USD","LU1989764748.USD","LU2028103732.USD","XBI","XLV","LU1989764664.SGD","LU0432979614.USD","LU0012050646.USD","LU0006306889.USD","IE00BVYPNV92.GBP","LU0106261372.USD","LU1506573853.SGD","LU0265550359.USD","LU2089283258.USD","BK4585","LU1244550577.SGD","LU0496365809.HKD","IE00BQXX3F31.USD","LU1989771016.USD","NEO","IE00B42XCP33.USD","LU0029874061.USD","LU0128526141.USD","BK4566","LU1291159041.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662744692","title":"NeoGenomics RaDaR ST Gains Expanded Medicare Coverage for Immunotherapy Response Monitoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2662744692","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662744692?lang=en_us&edition=fundamental","pubTime":"2026-08-27 04:19","pubTimestamp":1787775586,"startTime":"0","endTime":"0","summary":"NeoGenomics RaDaR ST gains expanded Medicare coverage for immunotherapy response monitoringNeoGenomics secured expanded Medicare coverage from CMS MolDX for its RaDaR ST MRD assay to monitor immunothe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL3k3Zl5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEO","FBT","LU0106261612.USD","LU0012050646.USD","BK4196","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662744512","title":"Neogenomics Receives Medicare Coverage for Radar St for Immunotherapy Treatment Response Monitoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2662744512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662744512?lang=en_us&edition=fundamental","pubTime":"2026-08-27 04:17","pubTimestamp":1787775420,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nTUA2J4Z9Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","NEO","LU0012050646.USD","LU0106261612.USD","FBT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662760351","title":"Circio and Full Circles join forces on non-viral in vivo cell therapy platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760351","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662760351?lang=en_us&edition=fundamental","pubTime":"2026-08-26 13:43","pubTimestamp":1787723005,"startTime":"0","endTime":"0","summary":"Targovax ASA ( ($GB:0RIS) ) just unveiled an announcement. Circio Holding ASA and Full Circles Therapeutics have entered a research collaboration t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/circio-and-full-circles-join-forces-on-non-viral-in-vivo-cell-therapy-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/circio-and-full-circles-join-forces-on-non-viral-in-vivo-cell-therapy-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBBQ","CNCR","SYNB","BK4585","GNOM","FBT","BK4588","TBXU","IBB","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662757992","title":"Court Win Over Natera Patents Could Be A Game Changer For NeoGenomics’ (NEO) RaDaR ST","url":"https://stock-news.laohu8.com/highlight/detail?id=2662757992","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662757992?lang=en_us&edition=fundamental","pubTime":"2026-08-26 03:24","pubTimestamp":1787685840,"startTime":"0","endTime":"0","summary":"NeoGenomics, Inc. previously announced that Alicia Olivo, EVP, General Counsel & Business Development, would step down as General Counsel in September 2026 and remain with the company until early October 2026 to support the transition.\nThe company also secured a favorable North Carolina court ruling that invalidated key Natera patents, reducing legal friction around its RaDaR ST assay and altering the competitive landscape in molecular residual disease testing.\nWe’ll now examine how this...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/court-win-over-natera-patents-could-be-a-game-changer-for-ne","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/court-win-over-natera-patents-could-be-a-game-changer-for-ne","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1064131342.USD","LU2065170008.USD","LU0345770993.USD","LU2065731478.USD","HELX","LU2065169927.USD","LU2065171402.SGD","LU2264538146.SGD","GNOM","BK4196","LU0963586101.USD","LU1988902786.USD","LU2324357040.USD","NEO","LU2065171311.SGD","LU0106261612.USD","LU0053671581.USD","BK4139","NTRA","LU0345770308.USD","FBT","BK4121","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662759663","title":"Circio bolsters board as it advances circular RNA gene therapy platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2662759663","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662759663?lang=en_us&edition=fundamental","pubTime":"2026-08-26 01:07","pubTimestamp":1787677640,"startTime":"0","endTime":"0","summary":"Targovax ASA ( ($GB:0RIS) ) has issued an announcement. Circio Holding ASA has strengthened its board of directors as it enters a new development p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/circio-bolsters-board-as-it-advances-circular-rna-gene-therapy-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/circio-bolsters-board-as-it-advances-circular-rna-gene-therapy-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYNB","BK4588","BK4505","TBXU","LFSC","RNA","IBB","IE0009354923.USD","FBT","IBBQ","BK4585","CNCR","GNOM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662620199","title":"Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2662620199","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662620199?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:30","pubTimestamp":1787610625,"startTime":"0","endTime":"0","summary":"Alkermes’ alixorexton posts positive Phase 2 Vibrance-1 results in narcolepsy type 1 studyAlkermes reported publication of positive Phase 2 Vibrance-1 results for alixorexton in adults with narcolepsy type 1 in The Lancet Neurology.Results were previously announced, not newly presented, showing improved daytime wakefulness and sleepiness measures versus placebo.Study also indicated reduced cataplexy at one dose, with broader patient-reported benefits in daily functioning.Safety profile appeared generally well tolerated, with mostly mild-to-moderate adverse events and no serious treatment-emergent events reported.Positive Phase 2 readouts supported the launch of the global Phase 3 Brilliance program testing once-daily and split-dose regimens in narcolepsy types 1 and 2.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL56tjq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","PSCH","MEDX","BK4139","IBRN","FBT","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201993","title":"The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201993?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:30","pubTimestamp":1787610600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA7VQ936:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","BK4139","MEDX","IBRN","PSCH","FBT","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271984","title":"Veracyte (VCYT) Receives a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271984","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271984?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:15","pubTimestamp":1787577318,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst David Westenberg maintained a Buy rating on Veracyte today and set a price target of $54.00. According to TipRanks, Westenber...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/veracyte-vcyt-receives-a-buy-from-piper-sandler-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/veracyte-vcyt-receives-a-buy-from-piper-sandler-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FBT","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271451","title":"Is Bruker’s (BRKR) AI Bet With Atinary Quietly Redefining Its Long-Term R&D Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271451","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271451?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:21","pubTimestamp":1787574101,"startTime":"0","endTime":"0","summary":"In August 2026, Bruker’s board declared a quarterly cash dividend of US$0.05 per share, payable on October 7, 2026, to shareholders of record as of September 21, 2026, while the company also expanded its collaboration with Atinary Technologies and took a minority stake in the AI-driven R&D firm. \nThe Atinary collaboration links Bruker’s analytical instruments and SciY software with AI-guided Self-Driving Lab workflows, aiming to automate complex chemical experimentation and generate...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/is-brukers-brkr-ai-bet-with-atinary-quietly-redefining-its-l","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/is-brukers-brkr-ai-bet-with-atinary-quietly-redefining-its-l","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARTY","BK4121","LU0757428866.USD","AIPO","QTOC","VTHR","AGIX","LU1815336091.USD","BRKR","CHAT","TINY","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661627309","title":"Regenxbio reports FDA placed clinical hold on RGX-121","url":"https://stock-news.laohu8.com/highlight/detail?id=2661627309","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661627309?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:20","pubTimestamp":1787570406,"startTime":"0","endTime":"0","summary":"Regenxbio (RGNX) provided an update on its investigational gene therapy, RGX-121, for the treatment of Mucopolysaccharidosis type II, also known as...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-reports-fda-placed-clinical-hold-on-rgx-121-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-reports-fda-placed-clinical-hold-on-rgx-121-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","CNCR","SYNB","GNOM","IBB","RGNX","FBT","BK4585","TBXU","BK4588","BK4563","LABU","BK4139","IBBQ","BK4505"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}